Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546816 · ClinicalTrials.gov registry record · Phase 3
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
A Phase 3 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 285
- Enrollment target
NCT03546816 is a Phase 3 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 285 participants.
The verdict
NCT03546816, a Phase 3 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 285 participants
- Enrollment target
Study Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
Interventions
- DRUG Placebo Tablets
- DRUG 5mg Serlopitant Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03546816
The ClinicalTrials.gov registry entry for NCT03546816 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT03546816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03546816 about?
NCT03546816 is a clinical study titled "Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis". Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
What is the current status of trial NCT03546816?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2018-05-02. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT03546816?
The interventions under investigation include: Placebo Tablets (DRUG), 5mg Serlopitant Tablets (DRUG).
Who is sponsoring clinical trial NCT03546816?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.